403 filings
6-K
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
6-K
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
6-K
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
REPCF
Replicel Life Sciences Inc.
19 Oct 23
Current report (foreign)
1:45pm
6-K
REPCF
Replicel Life Sciences Inc.
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
6-K
gc8pl7zc672uh0
13 Sep 23
RepliCel Announces DermaPreciseā¢ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
k8w5v0j xrh4kcqgee
7 Sep 23
Current report (foreign)
12:26pm
6-K
r9481o09as4lz9i04i
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
6-K
0ba2btexyr5prfyglxa
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
4nxd6 ku4fk7
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
sb444prhwdk7ncsq 7z
9 Aug 23
Statement of Executive Compensation
7:41pm
6-K
2099zm74
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
v4g8ugt19h59 37ca
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
dc9rci0 it2z4bly
21 Mar 23
RepliCel Announces Shareholder Approval of 10% Rolling Stock Option Plan
4:56pm
D
sglfrvtbpie184h7j
16 Mar 23
$740.78 k in equity / options / securities to be acquired, sold $740.78 k, 5 investors
2:39pm
6-K
e0jzwtzxwea699ph55s
23 Feb 23
RepliCel Announces Settlement of Payment of Dividend on Preferred Shares
11:54am
6-K
thsc r26u
23 Feb 23
RepliCel Life Sciences Announces Intention to Pay Dividend on Preferred Shares
11:42am
D
vaq3zg26o
7 Feb 23
$9.20 k in equity, sold $9.20 k, 1 investor
5:48pm
6-K
5g1j5bbf6be ce5
1 Feb 23
Current report (foreign)
6:58pm